A novel proof-of-concept study assessing the lightening effects and safety of malassezin for treatment of facial hyperpigmentation

Published: 10 January 2022| Version 4 | DOI: 10.17632/n65436ctw7.4
Contributors:
,
,
,
,
,
,
,
,
,

Description

This is the supplementary data for the Research Letter (Journal of the American Academy of Dermatology) DOI: https://doi.org/10.1016/j.jaad.2021.10.008 This data is provided by the authors to give readers additional information about their work. Purpose The primary objective of this seminal and first proof-of-concept, double-blind, dose-ranging study was to investigate the efficacy and safety of malassezin, a natural indole metabolite of Malassezia furfur, for mild, moderate, and severe facial hyperpigmentation secondary to photodamage or melasma. Conclusion Malassezin is a highly active agonist of the aryl hydrocarbon receptor with key homeostasis functions that may impact the mechanism of pigmentation reduction​ as shown by in vitro testing demonstrating that malassezin is not a tyrosinase inhibitor. The major strength of this investigation is the early onset of lightening visible at weeks 2 and 4 and the maintenance of improvement for 8 weeks after treatment, an outcome that has been rarely reported in other clinical trials.

Files

Categories

Medical Dermatology, Facial Skin, Malassezia, Pigmentary Disorder, Melasma

Licence